Glioblastoma Multiforme
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Here, we quantify baseline expression of MGMT and EGFR protein in newly diagnosed GBM samples using mass spectrometry.
|
31823165 |
2020 |
Glioblastoma Multiforme
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
We sought to characterize mRNA and protein content of EV subpopulations released by human glioblastoma (GBM) cells expressing a mutant form of epidermal growth factor receptor (U87<sup>EGFRvIII</sup>) <i>in vitro</i> and <i>in vivo</i> with respect to size, morphology and the presence of tumour cargo.
|
31839905 |
2020 |
Glioblastoma Multiforme
|
0.500 |
Biomarker
|
disease |
BEFREE |
U87 human GBM cells were treated with the IC50 concentration of various agents used in the treatment of GBM, including alkylating agents (temozolomide, carmustine, lomustine, procarbazine), inhibitor of topoisomerase I (irinotecan), vascular endothelial and epidermal growth factor receptor inhibitors (cediranib and erlotinib, respectively) anti-metabolite (5-fluorouracil), microtubule inhibitor (vincristine), and metabolic agents (dichloroacetate and IDH1 inhibitor ivosidenib).
|
30989436 |
2020 |
Glioblastoma Multiforme
|
0.500 |
Biomarker
|
disease |
BEFREE |
EGFR-amplified GBMs displayed both a higher number of concrete CNAs and a higher global tumor mutational burden than their no EGFR-amplified counterparts.
|
31751860 |
2020 |
Glioblastoma Multiforme
|
0.500 |
Biomarker
|
disease |
BEFREE |
However, EGFR amplification is poorly represented in glioblastoma cell lines.
|
30509096 |
2019 |
Glioblastoma Multiforme
|
0.500 |
Biomarker
|
disease |
BEFREE |
Here, we describe recent knowledge on the signaling pathways mediated by EGFR/EGFR variant III (EGFRvIII) with regard to current therapeutic strategies to target EGFR/EGFRvIII amplified glioblastoma.
|
31013819 |
2019 |
Glioblastoma Multiforme
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
We have previously shown that differential expression of the epidermal growth factor receptor in glioblastoma cells affects PpIX fluorescence.
|
31734545 |
2019 |
Glioblastoma Multiforme
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Genomic analyses reveal that signature genetic lesions in GBM and LGG include copy gain and amplification of chromosome 7, amplification, mutation, and overexpression of receptor tyrosine kinases (RTK) such as EGFR, and activating mutations in components of the PI3K pathway.
|
30530503 |
2019 |
Glioblastoma Multiforme
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
We recently reported that inhibiting EGFR leads to increased secretion of tumor necrosis factor (TNF) and activation of a survival pathway in GBM.
|
31363754 |
2019 |
Glioblastoma Multiforme
|
0.500 |
Biomarker
|
disease |
BEFREE |
We also identify a role of extracellular HA (via CD44) in altering the effect of erlotinib in GBM EGFR + cells by modifying STAT3 phosphorylation status.
|
31352310 |
2019 |
Glioblastoma Multiforme
|
0.500 |
Biomarker
|
disease |
BEFREE |
In this study, we established a matched pair of glioblastoma stem-like cell (GSC) cultures from patient glioblastoma samples before and after epidermal growth factor receptor (EGFR)-targeted therapy.
|
30644426 |
2019 |
Glioblastoma Multiforme
|
0.500 |
Biomarker
|
disease |
BEFREE |
In this study, we developed a cyclic peptide iRGD (CCRGDKGPDC)-conjugated solid lipid nanoparticle (SLN) to deliver small interfering RNAs (siRNAs) against both epidermal growth factor receptor (EGFR) and PD-L1 for combined targeted and immunotherapy against glioblastoma, the most aggressive type of brain tumors.
|
30916923 |
2019 |
Glioblastoma Multiforme
|
0.500 |
Biomarker
|
disease |
BEFREE |
Hence, we analyzed transcriptome data from glioblastoma cell line SF767 to predict target genes regulated by EGFR isoforms II-IV, but not by EGFR isoform I nor other receptors such as HER2, HER3, or HER4.
|
31438847 |
2019 |
Glioblastoma Multiforme
|
0.500 |
Biomarker
|
disease |
BEFREE |
The IC<sub>50</sub> values of the compounds against carcinoma cells varied from 16.90 µM (in resistant U87MG.ΔEGFR glioblastoma cells) to 48.67 µM (against HepG2 hepatocarcinoma cells) for 1, from 7.85 µM (in U87MG.ΔEGFR cells) to 14.44 µM (in resistant MDA-MB231/BCRP breast adenocarcinoma cells) for 2, from 4.96 µM (towards U87MG.ΔEGFRcells) to 7.76 µM (against MDA-MB231/BCRP cells) for 4, and from 0.07 µM (against MDA-MB231 cells) to 2.15 µM (against HepG2 cells) for doxorubicin.
|
30836216 |
2019 |
Glioblastoma Multiforme
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our data identify ALDH levels as a biomarker of GBM cells with high invasive potential, altered oxidative stress, and resistance to EGFR inhibition, and reveal a therapeutic target whose inhibition should limit GBM invasion.
|
31270152 |
2019 |
Glioblastoma Multiforme
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
D2C7-IT is a novel immunotoxin (IT) targeting wild-type epidermal growth factor receptor (EGFRwt) and mutant EGFR variant III (EGFRvIII) proteins in glioblastoma.
|
31142380 |
2019 |
Glioblastoma Multiforme
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Importantly, MYST1 expression was lowly expressed in mesenchymal subtype of GBM and was positively correlated with EGFR expression in a cohort from The Cancer Genome Atlas.
|
31691527 |
2019 |
Glioblastoma Multiforme
|
0.500 |
Biomarker
|
disease |
BEFREE |
Genetic Alterations of Epidermal Growth Factor Receptor in Glioblastoma: The Usefulness of Immunohistochemistry.
|
29912767 |
2019 |
Glioblastoma Multiforme
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
To take advantage of these traits, we developed a Drosophila GBM model with constitutively active variants of EGFR and PI3K that effectively recapitulated key aspects of GBM disease.
|
31520357 |
2019 |
Glioblastoma Multiforme
|
0.500 |
Biomarker
|
disease |
BEFREE |
We demonstrate our method using multimodal high-spectral resolution matrix-assisted laser desorption ionization (MALDI) 9.4 T MSI and 7 T in vivo MRI data, acquired from a patient-derived, xenograft mouse brain model of glioblastoma following administration of the EGFR inhibitor drug of Erlotinib.
|
30932478 |
2019 |
Glioblastoma Multiforme
|
0.500 |
Biomarker
|
disease |
BEFREE |
Amplification of epidermal growth factor receptor (EGFR) and active mutant EGFRvIII occurs frequently in glioblastoma (GBM) and contributes to chemo/radio-resistance in various cancers, especially in GBM.
|
31508283 |
2019 |
Glioblastoma Multiforme
|
0.500 |
Biomarker
|
disease |
BEFREE |
Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma.
|
31273577 |
2019 |
Glioblastoma Multiforme
|
0.500 |
Biomarker
|
disease |
BEFREE |
Importantly, AZD9291 inhibited GBM cell proliferation > 10 times more efficiently than the first-generation EGFR inhibitors.
|
31122294 |
2019 |
Glioblastoma Multiforme
|
0.500 |
Biomarker
|
disease |
BEFREE |
Chen and colleagues leverage a <i>Drosophila</i> GBM model to identify a conserved signaling axis downstream of the EGFR and PI3K that involves the death-associated protein kinase (Drak), a cytoplasmic serine/threonine kinase orthologous to the human kinase STK17A.
|
30877099 |
2019 |
Glioblastoma Multiforme
|
0.500 |
Biomarker
|
disease |
BEFREE |
Noncanonical genes in GB could be a key for future therapeutic strategies targeting EGFR-dependent gliomas.
|
30506943 |
2019 |